复星医药子公司布瑞基奥仑赛注射液药品注册申请获受理

Core Viewpoint - Fosun Pharma's subsidiary, Fosun Kerry (Shanghai) Biotechnology Co., Ltd., has had its drug registration application for Brexucabtagene Autoleucel injection accepted by the National Medical Products Administration, targeting adult patients with relapsed or refractory precursor B-cell acute lymphoblastic leukemia (ALL) [1] Group 1 - The drug application is specifically for treating adult patients with relapsed or refractory precursor B-cell acute lymphoblastic leukemia (ALL) [1] - Another indication for the product, aimed at adult patients with relapsed or refractory mantle cell lymphoma (r/r MCL) who have previously undergone second-line or higher treatment, is currently in the bridging clinical trial phase within mainland China (excluding Hong Kong, Macau, and Taiwan) [1]